Director Chin gets 22,500 Biomerica (BMRA) restricted shares grant
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Biomerica director Eric Chin reported an equity award of 22,500 shares of common stock on December 12, 2025. The grant was issued at $0 per share as restricted stock under the company’s 2024 Stock Incentive Plan. Following this award, he beneficially owns 32,500 common shares directly. The restricted stock will vest in full on the one-year anniversary of December 12, 2025, if he remains in continuous service, with potential accelerated vesting in certain events, including specified changes of control.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Chin Eric
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common stock | 22,500 | $0.00 | -- |
Holdings After Transaction:
Common stock — 32,500 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What did Biomerica (BMRA) director Eric Chin report in this Form 4 filing?
Biomerica director Eric Chin reported receiving an award of 22,500 shares of common stock. The shares were granted as restricted stock at $0 per share and increase his directly held beneficial ownership to 32,500 shares, subject to vesting conditions described in the award terms.
What are the vesting terms of Eric Chin’s 2025 Biomerica restricted stock award?
The restricted stock award will vest in full on the one-year anniversary of December 12, 2025. Vesting requires that Eric Chin remain in continuous service through that date, with the possibility of accelerated vesting upon certain events, including specified changes of control of Biomerica.
Under which plan was Eric Chin’s Biomerica restricted stock granted?
Eric Chin’s restricted stock was granted under Biomerica’s 2024 Stock Incentive Plan. The plan provided for the award of 22,500 shares of common stock as restricted stock, subject to time-based vesting and potential acceleration in certain circumstances outlined in the award terms.
Was there any cash paid for Eric Chin’s Biomerica restricted stock grant?
No cash was paid for the grant; the restricted stock was issued at $0 per share. The Form 4 shows a transaction price of $0.0000 for the 22,500 acquired shares, consistent with an equity compensation award rather than an open-market purchase.